Literature DB >> 8306101

Antagonism of levcromakalim by imidazoline- and guanidine-derivatives in rat portal vein: involvement of the delayed rectifier.

T Ibbotson1, G Edwards, A H Weston.   

Abstract

1. In rat whole portal veins, guanabenz (100 nM to 10 microM) and antazoline (100 nM to 100 microM) each increased the amplitude, frequency and duration of spontaneous contractions. In addition, guanabenz (30 microM) and antazoline (30 microM) each antagonized the ability of levcromakalim (3 nM to 10 microM) to inhibit the spontaneous contractions of this tissue. 2. Whole-cell voltage-clamp recordings were made from freshly-isolated rat portal vein cells dispersed by a collagenase/pronase enzyme treatment. The ability of several agents (antazoline, cirazoline, clonidine, guanabenz and phentolamine, each containing an imidazoline or guanidine moiety), to modulate potassium (K) currents and to inhibit the actions of levcromakalim was investigated. 3. Antazoline, cirazoline, clonidine, guanabenz and phentolamine (each at a concentration of 30 microM) had little effect on control non-inactivating currents but inhibited the delayed-rectifier current, IK(V). 4. Levcromakalim (1 microM) induced a non-inactivating current, IK(ATP), and also inhibited the delayed rectifier current, IK(V). 5. Glibenclamide (1 microM) had no effect on control delayed rectifier or non-inactivating currents, but it inhibited the simultaneous induction of IK(ATP) and reduction of IK(V) produced by levcromakalim (1 microM). 6. Antazoline, cirazoline, clonidine and guanabenz (each at a concentration of 30 microM) prevented the induction of IK(ATP) by levcromakalim (1 microM). Phentolamine (30 microM) and clonidine (30 microM) each inhibited the IK(ATP) generated by levcromakalim (1 microM). 7. It is concluded that a variety of agents which possess either an imidazoline (antazoline, cirazoline, clonidine and phentolamine) or a guanidine (guanabenz) moiety within their structure inhibit the delayed rectifier current, IK(V). This action may thus be mediated via a so-called non-adrenoceptor imidazoline binding site. Furthermore, the ability of these ligands to inhibit IK(V) and to antagonize both the induction of IK(ATP) and the vasorelaxation produced by levcromakalim is consistent with the view that the channel (KATP) which underlies IK(ATP) is a voltage-insensitive state of the delayed rectifier K-channel (Kv).

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8306101      PMCID: PMC2175856          DOI: 10.1111/j.1476-5381.1993.tb14001.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  31 in total

1.  Preferential support of Ca2+ uptake in smooth muscle plasma membrane vesicles by an endogenous glycolytic cascade.

Authors:  R J Paul; C D Hardin; L Raeymaekers; F Wuytack; R Casteels
Journal:  FASEB J       Date:  1989-09       Impact factor: 5.191

Review 2.  Effects of glyburide on carbohydrate metabolism and insulin action in the liver.

Authors:  J F Caro
Journal:  Am J Med       Date:  1990-08-20       Impact factor: 4.965

Review 3.  The pharmacology of ATP-sensitive potassium channels.

Authors:  G Edwards; A H Weston
Journal:  Annu Rev Pharmacol Toxicol       Date:  1993       Impact factor: 13.820

4.  Improved patch-clamp techniques for high-resolution current recording from cells and cell-free membrane patches.

Authors:  O P Hamill; A Marty; E Neher; B Sakmann; F J Sigworth
Journal:  Pflugers Arch       Date:  1981-08       Impact factor: 3.657

5.  Properties of the cromakalim-induced potassium conductance in smooth muscle cells isolated from the rabbit portal vein.

Authors:  D J Beech; T B Bolton
Journal:  Br J Pharmacol       Date:  1989-11       Impact factor: 8.739

6.  Characterization of an imidazoline/guanidinium receptive site distinct from the alpha 2-adrenergic receptor.

Authors:  A Parini; I Coupry; R M Graham; I Uzielli; D Atlas; S M Lanier
Journal:  J Biol Chem       Date:  1989-07-15       Impact factor: 5.157

7.  Cromakalim-induced relaxation of guinea-pig isolated trachealis: antagonism by glibenclamide and by phentolamine.

Authors:  M A Murray; J P Boyle; R C Small
Journal:  Br J Pharmacol       Date:  1989-11       Impact factor: 8.739

8.  Action potentials and net membrane currents of isolated smooth muscle cells (urinary bladder of the guinea-pig).

Authors:  U Klöckner; G Isenberg
Journal:  Pflugers Arch       Date:  1985-12       Impact factor: 3.657

9.  Phentolamine and structurally related compounds selectively antagonize the vascular actions of the K+ channel opener, cromromakalim.

Authors:  G A McPherson; J A Angus
Journal:  Br J Pharmacol       Date:  1989-07       Impact factor: 8.739

10.  Inhibition by glibenclamide of the vasorelaxant action of cromakalim in the rat.

Authors:  R E Buckingham; T C Hamilton; D R Howlett; S Mootoo; C Wilson
Journal:  Br J Pharmacol       Date:  1989-05       Impact factor: 8.739

View more
  5 in total

1.  Effects of cytochrome P450 inhibitors on potassium currents and mechanical activity in rat portal vein.

Authors:  G Edwards; P M Zygmunt; E D Högestätt; A H Weston
Journal:  Br J Pharmacol       Date:  1996-10       Impact factor: 8.739

Review 2.  Pharmacology of the potassium channel openers.

Authors:  G Edwards; A H Weston
Journal:  Cardiovasc Drugs Ther       Date:  1995-03       Impact factor: 3.727

3.  Block of pancreatic ATP-sensitive K+ channels and insulinotrophic action by the antiarrhythmic agent, cibenzoline.

Authors:  A Ishida-Takahashi; M Horie; Y Tsuura; H Ishida; T Ai; S Sasayama
Journal:  Br J Pharmacol       Date:  1996-04       Impact factor: 8.739

4.  Inhibition of delayed rectifier K(+)-current by levcromakalim in single intestinal smooth muscle cells: effects of cations and dependence on K(+)-flux.

Authors:  D McHugh; D J Beech
Journal:  Br J Pharmacol       Date:  1995-01       Impact factor: 8.739

5.  Ion channel modulation by NS 1619, the putative BKCa channel opener, in vascular smooth muscle.

Authors:  G Edwards; A Niederste-Hollenberg; J Schneider; T Noack; A H Weston
Journal:  Br J Pharmacol       Date:  1994-12       Impact factor: 8.739

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.